STEMCOR LIMITED
Company number 00501712 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Assessment: STEMCOR LIMITED
1. Financial Health Score: B+ (Provisional)
Explanation: Based on the available corporate DNA and structural indicators, Stemcor Limited presents as a robust, long-standing entity with excellent regulatory hygiene and substantial capital reserves. However, because the detailed "blood work" (specific profit, loss, and asset valuations from recent annual accounts) is not present in this dataset, a definitive grade cannot be issued. The B+ reflects strong structural health and compliance, but the grade is held in reserve pending a full review of the detailed financial statements.
2. Key Vital Signs
- Corporate Age & Resilience (Incorporated 1951): This is a mature patient. Having survived over 70 years of economic cycles, the company possesses a highly resilient corporate constitution. Businesses of this age have typically developed strong immune responses to market volatility.
- Capital Reserves (£10,000,000 Share Capital): The company exhibits excellent "bone density." A £10 million share capital indicates a substantial foundation of equity, meaning the company was capitalized with significant financial strength, providing a thick cushion against operational losses.
- Regulatory Pulse (Filing Compliance): The company's compliance vitals are strong. Accounts are filed up to 31 December 2025, with the next deadline not until September 2027, and confirmation statements are current. There are no signs of regulatory fever (overdue filings or penalties).
- Genetic Lineage (PSC & Ownership): The company is wholly owned by Stemcor Acquisitions Limited, which holds more than 75% of shares and voting rights. This indicates the company operates as a subsidiary—effectively an organ within a larger corporate body. Its financial circulatory system is intrinsically linked to its parent.
- Neurological Function (SIC Code 70100): Classified under "Activities of head offices," this company acts as the brain or central nervous system of the group, likely managing strategic direction, financing, or administrative holding functions rather than undertaking heavy operational trading itself.
3. Diagnosis
Structurally, Stemcor Limited shows no symptoms of distress. It is an active, compliant, well-capitalized entity with a long history of survival.
However, because the company operates as a "head office" and is wholly owned by Stemcor Acquisitions Limited, its individual health is somewhat masked by the group's consolidated health. Like an organ relying on the broader circulatory system, a head office entity often depends on group funding, inter-company loans, or dividends to sustain itself. Without viewing the specific balance sheet—specifically the net current assets and the P&L reserves—we cannot definitively rule out underlying conditions such as an over-reliance on inter-company debt or thin liquidity.
The change of name in 1988 (from Coutinho Caro & Co. Limited) and again in 2005 suggests historical corporate evolution or acquisitions, which aligns with its current status as part of a wider acquisition group. The presence of international directors (American and British) suggests a healthy, globalized strategic outlook.
4. Recommendations
To move from a provisional to a definitive state of financial wellness, the following "follow-up tests" and ongoing care routines are recommended:
- Conduct a Full Blood Panel (Review Detailed Accounts): Request and review the full, filed annual accounts at Companies House. Specifically, examine the net current assets (working capital) and the profit and loss reserve. This will reveal whether the company is generating its own healthy cash flow or relying on life support from the parent company (inter-company loans).
- Monitor the Parent's Health: Because Stemcor Limited is wholly owned and controlled by Stemcor Acquisitions Limited, any financial contagion in the parent company will immediately infect the subsidiary. Regular health checks on the parent entity are essential.
- Maintain Regulatory Hygiene: Continue the excellent track record of filing accounts and confirmation statements on time. Late filings act as symptoms of administrative distress and can incur financial penalties.